PRISM is organized around two main pillars, one devoted to Technological Innovations and the second to Therapeutic Innovations, both focused on early diagnosis and therapy. The technological innovations create tools, and the therapeutic innovations use these tools for therapeutic response.
Based on its long-standing background in mass spectrometry and proteomics, the technological innovation pillar developed spatial and single omics, subcellular network, and integrated multi-omics to characterized pathological tissues and track the biomarkers thanks to the development of new assays and sensors mainly based on mass spectrometry (Snoop-i for VOCS, BatMass for multiplex biomarker detection and EVs characterization). At the level of the innovation therapy pillar, the early diagnosis research is focused on cellular communication mechanisms and epigenetics for neurobiology of cancer and neuroimmunology.
The therapeutic approaches are devoted to next generation and precision surgery. It tackles new technological innovations with SpiderMass and IrosMass technologies associated to mass spectrometry based immune score and direct phototherapy while immune cell reprogramming is the objective in the therapeutic innovation pillar.
The Technological Innovation pillar is issued from the MALDI Imaging Team (MIT) created in 2004 by Prof. I. Fournier (ACI JCJC) and devoted to MALDI MS Imaging (MALDI MSI). MIT was one of the pioneer teams worldwide to develop MALDI MSI. More specifically, MIT has developed the multiplex MALDI-IHC, has unlocked the for MS Imaging and is now one of the world leaders in the field spatial proteomics guided by high spatial resolution MALDI MSI for clinical applications targeting precision medicine.
The technological innovation axis is organized in two work packages so-called Early diagnosis and Therapy. The Early diagnosis WP is based on developments of new tools to characterize spatially but also at the single cell and subcellular levels by OMICs the tissue microenvironment from pathological diseases. New captors based on mass spectrometry such SNOOPI for VOCs or BAT-MASS to track these biomarkers in fluids or on patches for diagnosis are currently in clinical trials ‘evaluation. The therapeutic WP is devoted to the next generation surgery through SpiderMass technology including immune mass-based score, in vivo molecular imaging (Deadpool)and photodirect therapy (IrosMass). Several clinical trials using SpiderMass technology are under investigation such as sarcoma, Ovarian Cancer and Breast Cancer (SITH, Maverick, SETH).
Early Diagnosis
Therapy
The Therapeutic Innovation pillar is issued from neuroimmune research developed by Prof. M. Salzet since 2002 on neuroendocrine factors expression in macrophages and their role in the immune response. Such results have led us to reconsider the term neuroendocrine, not only as cells that secrete their products in a regulated manner, in response to a specific stimulus but to also include the notion that activation of specific genetic switches can lead to the expression of a partial or full neuroendocrine phenotype in a variety of cell types, including immune cells or neuroendocrine cancer cells. Thus, besides functional similarities, there is potentially a particular developmental link that bridges the neuroendocrine and immune system.
The Therapeutic Innovation axis is also organized in two work packages so-called Early diagnosis (WP&) and Therapy (WP2). WP1 use tools developed by the technological innovation pillar to investigate both cellular communications and mechanisms in context of neuroendocrine cancers and neuroimmune response. WP2 is devoted to immune cells reprogramming especially in context of tumors or brain inflammation. WP2 will be mainly focused on immune factors linked to tumor immunotolerance issued from alternative ORF. Such investigations will lead developments of specific therapies including CAR-Macrophages developments and new vaccine using ghost immunopeptides. Astrocyte reprogramming in glioblastoma is also investigated through the study of neural Ig inhibition and antigen recognition. While WP1 is devoted to basic sciences, WP2 is a translational theme to clinical settings based on the study in breast cancer and glioblastoma.
Early Diagnosis
Therapy
